🩺 Can dual antithrombotic therapy after PCI be safely shortened to just 1 month in patients with atrial fibrillation?

🩺 Can dual antithrombotic therapy after PCI be safely shortened to just 1 month in patients with atrial fibrillation? The OPTIMA-AF trial suggests that an earlier transition to DOAC monotherapy significantly reduces clinically relevant bleeding while maintaining similar protection against death and thromboembolic events. Although the findings require confirmation in broader populations, this study could influence how we individualize antithrombotic therapy after PCI. 🎙️ In this episode of Dr RR Baliga's Podkast for the Kurious Doc, we review the trial, its clinical implications, and the important caveats for everyday practice. #Cardiology #AtrialFibrillation #PCI #MedicalEducation